Cardiff and Swansea scan trial targets head cancers
Detailed imaging techniques are to help doctors target head and neck cancers more effectively in a £720,000 clinical trial.
By Owain ClarkeBBC Wales health correspondent It aims to improve the treatment and survival rates at Cardiff's Velindre and Swansea's Singleton hospital. The 3D scanning pinpoints the exact site of a tumour and maps the cancer's behaviour more accurately to target it with radiotherapy. The trial, starting later this year, is being funded by two charities. It will combine modern radiotherapy with advanced medical imaging, known as PET. Doctors say this sort of PET scanning not only sees the tumour's outline, as it would on a CT or MRI scan, but it also sees the tumour's activity. This provides far more detail and it is hoped it will give doctors an insight into how the cancer responds to treatment. "We inject patients with a radioactive sugar which is taken up by tumour cells, because they're dividing very rapidly, and then we can see that sugar that accumulates in the tumour on a scan like a PET CT scan," said consultant oncologist Dr Mererid Evans. "It's not just anatomical, it gives us a measure of how the tumour is behaving." Dr Evans said it was the first example of so-called "dose painting" in Wales and it has not been done before with computer modelling to target the cancer. "What we're planning with the research is to do PET CT scans, not just before treatment to help us target tumours better, but also during treatment so we can see how the tumour is responding to treatment," she added. "So we will be able to potentially adapt the radiotherapy during the course of treatment to give a higher dose to those very active areas of the tumour." These type of tumours are being researched because of the complex anatomy of the head and neck. Once patients on the trial have received initial radiotherapy to eradicate the bulk of the cancer, they will then undergo the PET scans on a £1.8m machine at Cardiff University's £18m PETIC facility. Dr Tom Crosby, clinical lead for the Moondance programme at Velindre cancer hospital in Cardiff which has helped fund the trial, said it would provide better outcomes for patients. He added: "This personalised approach offers the possibility of achieving the holy grail of precision oncology, hitting the tumours harder with higher doses of radiation, improving the chance of disease control and possibly cure, whilst sparing normal tissues which when damaged can lead to disabling long terms side effects." Prof John Moore, president of Cancer Research Wales which is also part-funding it, said, if successful, the "ground-breaking technology" could be transferred to other UK cancer centres and used to treat other tumour types.